July 16, 2024
2 min watch
On this video, Eric Winer, MD, discusses the outcomes of analysis into power myeloid leukemia introduced at ASCO Annual Assembly.
Winer, a medical oncologist at Dana-Farber Most cancers Institute, highlighted a research that examined using the STAMP inhibitor asciminib (Scemblix, Novartis) in power myeloid leukemia somewhat than the extra customary tyrosine kinase inhibitors or imatinib.
“If this bears out over time, then we might begin to use asciminib extra within the front-line setting, whereas proper now it is actually solely permitted within the third-line setting or in sufferers which have a T359 mutation. And so, this may very well be a major change — an advance in the way in which we deal with CML,” Winer stated.
